Investigational drug · Phase 2
INP20
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Peanut Allergy.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 30, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "INP20"
First trial start
2020
Mar 11, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INP20", any sponsor or status.
Conditions studied
As listed on its trial records.
- Peanut Allergy
Largest trials
Live from ClinicalTrials.gov: studies naming "INP20" as an intervention, largest first.
InnoUp Farma S.L.Industry
NCT04163562 · 50 participants (planned) · Start Mar 11, 2020 · Primary completion May 2025
Drug: INP20; Placebo · For: Peanut Allergy
Sites: Pamplona, Spain · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Peanut Allergy
- DBV712ViaskinTM PeanutPhase 32 trials
DBV Technologies · Allergy, Peanut, Peanut Allergy
- ENP-501Phase 21 trial
N-Fold, LLC · Peanut Allergy
- PVX-108Phase 21 trial
Aravax Pty Ltd · Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis
- UKK-0018Phase 21 trial
Ukko Inc · Peanut-Induced Anaphylaxis, Peanut Allergy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.